



an Open Access Journal by MDPI

The Role of NK Cells in Health and Diseases

Guest Editor:

Message from the Guest Editor

Dr. Matthew Blunt

School of Clinical and
Experimental Sciences, Faculty of
Medicine, University of
Southampton, Southampton
SO16 6YD, UK

Natural killer (NK) cells possess the ability to rapidly lyse tumour cells and promote the anti-cancer activity of other immune cell types, including macrophages, CD8⁺ T cells and dendritic cells.

Deadline for manuscript
submissions:

15 January 2025

Increased knowledge of the role of NK cells in hematological malignancies will provide new avenues for research and allow for improved utilization against tumour cells in the clinical setting. In this Special Issue, we invite investigators to contribute original research, as well as review articles, that address recent advances in NK cell function with regard to haematological malignancies. We welcome authors to submit manuscripts that provide novel insights on NK cell biology and therapeutic strategies including CAR-NK cells, cytokines, tumour-targeting antibodies, NK cell engagers, and checkpoint inhibitors.

Keywords: NK cells; lymphoma; multiple myeloma; CLL; AML; leukaemia; immunotherapy



mdpi.com/si/192683

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPlus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI